Show results for
Refine by
Allogeneic Cell Equipment & Supplies Near Germany
47 equipment items found
by:Scinogy Pty Ltd based inVictoria, AUSTRALIA
Scinogy's allogeneic cell processing systems are uniquely configured to realize economies of scale and optimize facility, equipment and staff utilization. These automated and integrated systems are designed to consistently processes multiple batches on any given day. Closed, single use kits enable parallel processing of multiple batches in a common, lower ...
Manufactured by:Bone Therapeutics SA based inMont-St-Guibert, BELGIUM
ALLOB is the Company’s off-the-shelf, allogeneic cell therapy platform consisting of human allogeneic bone-forming cells derived from ex-vivo cultured bone marrow mesenchymal stromal cells (MSC) from healthy adult donors, offering numerous advantages in product quality, injectable quantity, production, ...
Manufactured by:healiva SA based inLugano, SWITZERLAND
Our scalable treatment for chronic leg ulcers that are not responding to standard of care, using automated ...
by:Caribou Biosciences, Inc. based inBerkeley, CALIFORNIA (USA)
Our next-generation chRDNA genome-editing platform is the foundation for the development of differentiated allogeneic cell therapies. Our chRDNA technology enables multiple genome edits, including multiplex gene insertions, with a high degree of specificity and lower levels of off-target editing than first generation CRISPR-Cas9. ...
by:Thermo Fisher Scientific, LIMS & Laboratory Software based inPhiladelphia, PENNSYLVANIA (USA)
Gibco CTS OpTmizer Pro SFM is a novel medium, developed for the growth and expansion of human T lymphocytes (e.g., CD4+, CD8+, polyclonal cells, or antigen specific T cells) used in allogeneic cell therapies. CTS OpTmizer Pro SFM improves central memory phenotype and cell growth by shifting the ...
by:Vor Biopharma based inCambridge, MASSACHUSETTS (USA)
We believe VCAR33 could be a potent anticancer therapy that, when combined with VOR33, could help obviate severe on-target myeloablative toxicities and unlock the efficacy potential of VCAR33. In addition, in this setting, VCAR33 T cells could be sourced from the same cell source as VOR33 (allogeneic cells), which may provide ...
Manufactured by:Stempeutics Research Pvt. Ltd. based inBangalore, INDIA
Stempeucel® is our flagship product. It is an on-demand, off-the-shelf product based on pooled, allogeneic Mesenchymal Stromal Cells (MSC) derived from bone marrow of healthy, adult volunteers. In August 2020, Drug Controller General of India (DCGI) has granted manufacturing and marketing approval of Stempeucel® product for the treatment of CLI due to ...
by:Vor Biopharma based inCambridge, MASSACHUSETTS (USA)
VCAR33ALLO uses allogeneic healthy donor-derived cells. There has been an increasing appreciation for the value of cell phenotype in CAR-T approaches, and HLA-matched healthy donor cells are a potentially superior cell phenotype with improved persistence and in vivo expansion ...
Manufactured by:TC BioPharm based inHolytown, UNITED KINGDOM
TCB007 is an unmodified allogeneic gamma delta T cell product, being used for the treatment of COVID-19. This product is at the CTA application stage and is expected to enter phase 1 trials in summer 2020. ...
by:Chimeric Therapeutics based inCarlton South, AUSTRALIA
CHM 1301 (CLTX CAR NK) will be developed on the next generation CORE-NK platform leveraging our CLTX Chimeric Antigen ...
by:Chimeric Therapeutics based inCarlton South, AUSTRALIA
CHM 3301 (Undisclosed CAR NK) will be developed on the next generation CORE-NK platform leveraging a currently undisclosed Chimeric Antigen ...
by:Chimeric Therapeutics based inCarlton South, AUSTRALIA
CHM 2301 (CDH17 CAR NK) will be developed on the next generation CORE-NK platform leveraging our CDH17 Chimeric Antigen ...
by:Chimeric Therapeutics based inCarlton South, AUSTRALIA
The CORE-NK platform is a transformative platform technology for Chimeric enabling the accelerated development of multiple next generation, off the shelf NK and CAR-NK products. Natural killer cells are found in our bodies naturally and are able to recognize and kill cancer cells – but are not robust and active enough to overcome cancer as it grows. CORE-NK platform cells are made by ...
Manufactured by:Khloris Biosciences, Inc. based inMountain View, CALIFORNIA (USA)
Khloris' iPSCs are optimized to generate high-functioning cardiomyocytes, enabling development of an allogeneic source of donor cells for patients with damaged heart ...
Manufactured by:Bone Therapeutics SA based inMont-St-Guibert, BELGIUM
Bone Therapeutics is bringing a unique value proposition by developing a range of innovative bone cell therapy products administrable via a minimally invasive technique. ...
Manufactured by:ASC Therapeutics based inMilpitas, CALIFORNIA (USA)
Stem cells, including inducible pluripotent stem cells, mesenchymal stem cells (MSCs) and other primary pluripotent cells, hold the potential to treat a variety of diseases. We are currently focusing on developing an allogeneic decidua stromal cells (DSCs)-based platform to treat severe ...
by:Vor Biopharma based inCambridge, MASSACHUSETTS (USA)
Knocking out CD33 and CLL-1 through gene editing offers a promising new approach to treating patients with AML using our novel eHSC platform. Our research demonstrates that multiplex genome editing of allogeneic hematopoietic stem cells may represent another exciting strategy to efficiently and safely edit multiple genes in blood stem cells, ...
Manufactured by:Senti Biosciences based inSouth San Francisco, CALIFORNIA (USA)
The product profile of SENTI-301 has the potential to promote expansion and persistence of NK cells, and activate and recruit the body’s own immune cells into the solid tumor microenvironment for enhanced anti-tumor activity. ...
Manufactured by:RoosterBio, Inc. based inFrederick, MARYLAND (USA)
cGMP xeno-free human bone marrow-derived MSCs to support allogenic therapeutic cell manufacturing. Using a comprehensive and qualified supply chain of our high volume, well-characterized, and standardized WCBs (working cell banks) for large scale cell manufacturing – you’re now able to bypass major steps in cGMP ...
Manufactured by:Alphageneron based inCambridge, MASSACHUSETTS (USA)
Chimeric Antigen Receptor (CAR) NK Cells: Alphageneron is developing ‘off-the- shelf’ umbilical cord (UC) blood- and induced pluripotent stem cell (iPSC)-derived CAR-engineered NK (CAR NK) cell-based cancer therapeutics that target tumors expressing mHsp70, and other (undisclosed) targets. Gene editing of allogeneic ...